GPR39 (zinc receptor) knockout mice exhibit depression-like behavior and CREB/BDNF down-regulation in the hippocampus

International Journal of Neuropsychopharmacology

Volumn 18, Issue 3, 2015, Pages

  Mlyniec, Katarzyna ^a   Budziszewska, Boguslawa ^a,b   Holst, Birgitte ^c   Ostachowicz, Beata ^d   Nowak, Gabriel ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AGH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Poland)

Author keywords

CREB; Depression; GPR39; HPA axis; Zinc receptor

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CORTICOSTERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID RECEPTOR; GPR39 PROTEIN; UNCLASSIFIED DRUG; ZINC; CREBBP PROTEIN, MOUSE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GPR39 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DOWN REGULATION; FORCED SWIM TEST; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILITY; KNOCKOUT MOUSE; LIGHT-DARK TEST; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; TAIL SUSPENSION TEST; WESTERN BLOTTING; ZINC DEFICIENCY; ANIMAL; BLOOD; C57BL MOUSE; DARK ADAPTATION; DEFICIENCY; DISEASE MODEL; GENETICS; IMMOBILIZATION; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; SWIMMING; TIME FACTOR; TONIC IMMOBILITY;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CREB-BINDING PROTEIN; DARK ADAPTATION; DEPRESSION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HINDLIMB SUSPENSION; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; RECEPTOR, TRKB; RECEPTORS, G-PROTEIN-COUPLED; SWIMMING; TIME FACTORS; ZINC;

EID: 85005865085     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu002     Document Type: Article

References (51)

1. Besser L, Chorin E, Sekler I, Silverman WF, Atkin S, Russell JT, Hershfnkel M (2009) Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus. J Neurosci 29:2890-2901.
2. Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161.
3. Chorin E, Vinograd O, Fleidervish I, Gilad D, Herrmann S, Sekler I, Aizenman E, Hershfnkel M (2011) Upregulation of KCC2 activity by zinc-mediated neurotransmission via the mZnR/GPR39 receptor. J Neurosci 31:12916-12926.
4. Depoortere I (2012) GI functions of GPR39: novel biology. Curr Opin Pharmacol 12:647-652.
5. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pan-dey GN (2003) Altered gene expression of brain-derived neuro-trophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60:804-815.
6. Egerod KL, Holst B, Petersen PS, Hansen JB, Mulder J, Hökfelt T, Schwartz TW (2007) GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Mol Endocrinol 21:1685-1698.
7. Fava M, Davidson KG (1996) Defnition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
8. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. Am J Psychiatry 165:342-351.
9. Frederickson CJ, Koh JY, Bush AI (2005) The neurobiology of zinc in health and disease. Nat Rev Neurosci 6:449-462.
10. Gao H-L, Xu H, Xin N, Zheng W, Chi Z-H, Wang Z-Y (2011) Disruption of the CaMKII/CREB signaling is associated with zinc defciency-induced learning and memory impairments. Neu-rotox Res 19:584-591.
11. Haile CN, Murrough JW, Iosifescu D V, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney JJ, De La Garza R, Charney DS, Newton TF, Mathew SJ (2014) Plasma brain derived neuro-trophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17:331-336.
12. Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005) Lim-bic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29:1201-1213.
13. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW (2004) Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem 279:53806-53817.
14. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach L-O, Storjohann L, Stidsen CE, Jones R, Beck-Sickinger AG, Schwartz TW (2007) GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148:13-20.
15. Holst B, Egerod KL, Jin C, Petersen PS, Østergaard MV, Hald J, Sprinkel a ME, Størling J, Mandrup-Poulsen T, Holst JJ, Thams P, Orskov C, Wierup N, Sundler F, Madsen OD, Schwartz TW (2009) G protein-coupled receptor 39 defciency is associated with pancreatic islet dysfunction. Endocrinology 150:2577-2585.
16. Ishitobi Y, Akiyoshi J, Honda S, Ninomiya T, Kanehisa M, Tanaka Y, Tsuru J, Isogawa K, Kitamura H, Fujikura Y (2012) Administration of antisense DNA for GPR39-1b causes anxiolytic-like responses and appetite loss in rats. Neurosci Res 72:257-262.
17. Jackson VR, Nothacker H-P, Civelli O (2006) GPR39 receptor expression in the mouse brain. Neuroreport 17:813-816.
18. Lara DR, Bisol LW, Munari LR (2013) Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 16:2111-2117.
19. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R (1997) Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/infammatory response in that illness. Biol Psychiatry 42:349-358.
20. Maes M, De Vos N, Demedts P, Wauters A, Neels H (1999) Lower serum zinc in major depression in relation to changes in serum acute phase proteins. J Affect Disord 56:189-194.
21. Malkesman O, Austin DR, Tragon T, Wang G, Rompala G, Hamidi AB, Cui Z, Young WS, Nakazawa K, Zarate CA, Manji HK, Chen G (2012) Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol 15:1135-1148.
22. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012) Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26:189-204.
23. McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, Howard AD, Van der Ploeg LH (1997) Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 46:426-434.
24. Młyniec K, Davies CL, Budziszewska B, Opoka W, Reczynski W, Sowa-Kucma M, Doboszewska U, Pilc A, Nowak G (2012) Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. Pharmacol Rep 64:567-575.
25. Młyniec K, Budziszewska B, Reczynski W, Doboszewska U, Pilc A, Nowak G (2013a) Zinc defciency alters responsiveness to antidepressant drugs in mice. Pharmacol Rep 65:579-592.
26. Młyniec K, Budziszewska B, Reczynski W, Sowa-Kucma M, Nowak G (2013b) The role of the GPR39 receptor in zinc defcient-ani-mal model of depression. Behav. Brain Res 238:30-35.
27. Młyniec K, Davies CL, de Agüero Sánchez IG, Pytka K, Budzisze-wska B, Nowak G (2014a) Essential elements in depression and anxiety. Part I. Pharmacol Rep 4:534-544.
28. Młyniec K, Doboszewska U, Szewczyk B, Sowa-Kucma M, Misztak P, Piekoszewski W, Trela F, Ostachowicz B, Nowak G (2014b) The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims. Neuropharmacology 79:290-297.
29. Młyniec K, Nowak G (2012) Zinc defciency induces behavioral alterations in the tail suspension test in mice. Effect of anti-depressants. Pharmacol Rep 64:249-255.
30. Młyniec K, Nowak G (2013) GPR39 up-regulation after selective antidepressants. Neurochem Int 62:936-939.
31. Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Roberts RC, Conley RR (2007) Cyclic AMP response element-binding protein in postmortem brain of teenage suicide victims: specifc decrease in the prefrontal cortex but not the hippocampus. Int J Neu-ropsychopharmacol 10:621-629.
32. Pilc A, Wieronska JM, Skolnick P (2013) Glutamate-based antide-pressants: preclinical psychopharmacology. Biol Psychiatry 73:1125-1132.
33. Pochwat B, Pałucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G (2014) NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs 1-12.
34. Popovics P, Stewart AJ (2011) GPR39: a Zn(2+)-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell Mol Life Sci 68:85-95.
35. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharma-codyn thérapie 229:327-336.
36. Ranjbar E, Kasaei MS, Mohammad-Shirazi M, Nasrollahzadeh J, Rashidkhani B, Shams J, Mostafavi S-A, Mohammadi MR (2013) Effects of zinc supplementation in patients with major depression: a randomized clinical trial. Iran J Psychiatry 8:73-79.
37. Singewald N, Sinner C, Hetzenauer A, Sartori SB, Murck H (2004) Magnesium-defcient diet alters depression-and anxiety-related behavior in mice-infuence of desipramine and Hypericum perforatum extract. Neuropharmacology 47:1189-1197.
38. Siwek M, Szewczyk B, Dudek D, Styczen K, Sowa-Kucma M, Młyniec K, Siwek A, Witkowski L, Pochwat B, Nowak G (2013) Zinc as a marker of affective disorders. Pharmacol Rep 65:1512-1518.
39. Skolnick P (2002) Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids 23:153-159.
40. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepres-sants: 20 years on. Trends Pharmacol Sci 30:563-569.
41. Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Hari-moto T, Lanctôt KL (2013a) Zinc in depression: a meta-analy-sis. Biol Psychiatry 74:872-878.
42. Swardfager W, Herrmann N, McIntyre RS, Mazereeuw G, Gold-berger K, Cha DS, Schwartz Y, Lanctôt KL (2013b) Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci Biobehav Rev 37:911-929.
43. Szewczyk B, Kubera M, Nowak G (2011) The role of zinc in neu-rodegenerative infammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry 35:693-701.
44. Takeda A, Tamano H (2012) Proposed glucocorticoid-mediated zinc signaling in the hippocampus. Metallomics 4:614-618.
45. Tamano H, Kan F, Kawamura M, Oku N, Takeda A (2009) Behavior in the forced swim test and neurochemical changes in the hippocampus in young rats after 2-week zinc deprivation. Neurochem Int 55:536-541.
46. Tassabehji NM, Corniola RS, Alshingiti A, Levenson CW (2008) Zinc defciency induces depression-like symptoms in adult rats. Physiol Behav 95:365-369.
47. Ustun TB (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386-392.
48. Watanabe M, Tamano H, Kikuchi T, Takeda A (2010) Susceptibility to stress in young rats after 2-week zinc deprivation. Neuro-chem Int 56:410-416.
49. Whittle N, Lubec G, Singewald N (2009) Zinc defciency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice. Amino Acids 36:147-158.
50. Yasuda S, Miyazaki T, Munechika K, Yamashita M, Ikeda Y, Kamizono A (2007) Isolation of Zn2+ as an endogenous agonist of GPR39 from fetal bovine serum. J Recept Signal Transduct Res 27:235-246.
51. Yasuda S-I, Ishida J (2014) GPR39-1b, the 5-transmembrane iso-form of GPR39 interacts with neurotensin receptor NTSR1 and modifes its function. J Recept Signal Transduct Res 9893:1-6.